WHO Technical Report Series, No. 981 - World Health Organization

Acknowledgements
Madrid, Spain; Swedish Pharmacopoeia, Uppsala, Sweden; Swiss Pharmacopoeia,
Berne, Switzerland; Ukrainian Pharmacopoeia, Kharkov, Ukraine; United States
Pharmacopeia, Rockville, MD, USA; Vietnamese Pharmacopoeia, Hanoi, Viet Nam.
WHO Centre Collaborateur pour la Conformité des Médicaments,
Laboratoire national de Contrôle des Produits Pharmaceutiques, Alger, Algeria;
WHO Collaborating Centre for Drug Quality Assurance, Therapeutic Goods
Administration Laboratories, Woden, ACT, Australia; WHO Collaborating
Centre for Drug Quality Assurance, National Institutes for Food and Drug
Control, Beijing, People’s Republic of China; WHO Collaborating Centre for
Research on Bioequivalence Testing of Medicines, Frankfurt am Main, Germany;
WHO Collaborating Centre for Drug Information and Quality Assurance,
National Institute of Pharmacy, Budapest, Hungary; WHO Collaborating Centre
for Quality Assurance of Essential Drugs, Central Drugs Laboratory, Calcutta,
India; WHO Collaborating Centre for Regulatory Control of Pharmaceuticals,
National Pharmaceutical Control Bureau, Jalan University, Ministry of Health,
Petaling Jaya, Malaysia; WHO Collaborating Centre for Medicines Quality
Assurance, Pharmaceutical Laboratory, Centre for Analytical Science, Health
Sciences Authority, Singapore; WHO Collaborating Centre for Quality Assurance
of Medicines, North-West University, Potchefstroom, South Africa; WHO
Collaborating Centre for Quality Assurance of Essential Drugs, Bureau of Drug
and Narcotic, Department of Medical Sciences, Ministry of Public Health,
Nonthaburi, Thailand.
Anti-Counterfeiting Medicines Programme, WHO, Geneva, Switzerland;
Blood Products and Related Biologicals Programme, WHO, Geneva, Switzerland;
Global Malaria Programme, WHO, Geneva, Switzerland; HIV/AIDS Programme,
WHO, Geneva, Switzerland; International Nonproprietary Names Programme,
WHO, Geneva, Switzerland; Medicines Access and Rational Use, WHO,
Geneva, Switzerland; Medicines Regulatory Support Programme, WHO,
Geneva, Switzerland; Office of the Legal Counsel, WHO, Geneva, Switzerland;
Prequalification of Medicines Programme, WHO, Geneva, Switzerland; Quality,
Assurance and Safety: Medicines, WHO, Geneva, Switzerland; Quality, Safety
and Standards, WHO, Geneva, Switzerland; Traditional and Complementary
Medicine, WHO, Geneva, Switzerland; WHO Regional Office for Africa, Brazzaville,
Congo; WHO Regional Office for the Americas/Pan American Health Organization,
Washington, DC, USA; WHO Regional Office for the Eastern Mediterranean, Cairo,
Egypt; WHO Regional Office for Europe, Copenhagen, Denmark; WHO Regional
Office for South-East Asia, New Delhi, India; WHO Regional Office for the Western
Pacific, Manila, Philippines.
Mrs T. Abdul Sattar, Acting Director General, Directorate General of
Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman;
Dr F. Abiodun, Benin City, Nigeria; Dr E. Adams, Laboratorium voor
Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium;
47